# Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling

> **NCT02435563** · PHASE2 · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ticagrelor 180 mg administrated alone
- **DRUG:** Ticagrelor adjusted dose + ritonavir 100mg

## Key facts

- **NCT ID:** NCT02435563
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435563, "Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02435563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*